Clinical Trials Logo
  1. Home
  2. Pneumococcal Disease
  3. NCT00843895
  4. Details
NCT00843895 Clinical Trial

Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years

Pneumococcal Disease Clinical Trial

— Pneumococci  

Official title:
Serotyping of Pneumococci

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT00843895
Other study ID # kingsadu
Secondary ID
Status Not yet recruiting
Phase N/A
First received February 9, 2009
Last updated February 11, 2009
Start date March 2009
Est. completion date December 2009

Study information
Verified date February 2009
Source King Saud University
Contact Atef M. Shibl, PH D
Phone 00966505 30 2775
Email amshibl@ksu.edu.sa
Is FDA regulated No
Health authority Saudi Arabia: Research Advisory Council
Study type Interventional

Clinical Trial Summary

The purpose of this study is to identify the S. pneumoniae serotypes strains and to determine antibiotic susceptibility.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 400
Est. completion date December 2009
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group N/A to 5 Years
Eligibility Inclusion Criteria:

- age less than 5 years

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening

Related Conditions & MeSH terms

Intervention

Biological:
• pneumococcal conjugate vaccine(prevenar)
to see the vaccine impact on pneumococcal diseases

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
King Saud University

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence and serotypes of invasive pneumococcal dis. 6-8 months No
Secondary Antibiotic susceptibility 6-8 months No
See also
  Status Clinical Trial Phase
Completed NCT04546425 - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants Phase 3
Recruiting NCT06044077 - A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Phase 3
Completed NCT02146365 - Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
Completed NCT04525599 - A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator Phase 1
Active, not recruiting NCT05512819 - A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan Phase 3
Completed NCT04530838 - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants Phase 3
Active, not recruiting NCT06026748 - A Phase I Study of XJ103 in Chinese Healthy Subjects Phase 1
Completed NCT04526574 - Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age Phase 3
Completed NCT05329259 - A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India Phase 4
Completed NCT00234338 - Study Evaluating Prevenar in High-Risk Children N/A
Completed NCT01767402 - Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults Phase 1
Active, not recruiting NCT05569954 - Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) Phase 3
Completed NCT01111214 - Child Pneumococcal Serotype Epidemiology In Greece N/A
Completed NCT01298544 - A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers Phase 4
Completed NCT04830358 - Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults Phase 1
Completed NCT04379713 - 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants Phase 3
Completed NCT04887948 - Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 Phase 3
Completed NCT04382326 - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants Phase 3
Completed NCT01734239 - A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) Phase 3
Completed NCT05408429 - Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 Phase 3